IMUNON Appoints Dr. Douglas V. Faller as Chief Medical Officer

IMUNON, Inc. (NASDAQ: IMNN) has appointed Dr. Douglas V. Faller as Chief Medical Officer, effective February 18, 2025. Dr. Faller will oversee the company’s clinical strategy, focusing on IMNN-001, a DNA-mediated immunotherapy for newly diagnosed advanced ovarian cancer, which is set to enter a Phase 3 pivotal trial in Q1 2025.

Dr. Faller brings over 30 years of experience in biotech and pharmaceuticals, with leadership roles at Skyhawk Therapeutics, Oryzon Genomics, and Takeda, where he developed late-stage therapies, including CAR-T treatments. His academic background includes positions at Harvard Medical School and Boston University.

IMUNON CEO Stacy Lindborg, Ph.D., highlighted Dr. Faller’s extensive expertise in oncology and immunology as key to accelerating IMNN-001’s progress toward commercialization. Dr. Faller expressed enthusiasm for the company’s innovative immunotherapy approach, particularly the promising Phase 2 OVATION 2 Study data demonstrating significant improvements in survival outcomes.